<unk>  (also known as SR141716; trade names Acomplia, Zimulti) is an anorectic antiobesity drug that was first approved in Europe in 2006 but was withdrawn worldwide in 2008 due to serious psychiatric side effects; it was never approved in the United States.<unk>  is an inverse agonist for the cannabinoid receptor CB1 and was the first drug approved in that class.
Rimonabant
Beractant
Belinostat
Chlortalidone
Selegiline
Fosaprepitant
Rasagiline
Pirfenidone